Biocon Pharma Limited, a wholly-owned subsidiary of Biocon, has secured approval from the U.S. Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application (ANDA) for Liraglutide Injection.
The approved product, a generic version of Victoza®, is a 18 mg/3 mL (6 mg/mL) single-patient-use prefilled pen indicated for the treatment of insufficiently controlled Type 2 Diabetes Mellitus in adults, adolescents, and children aged 10 years and above, as an adjunct to diet and exercise. This follows a recent approval for Liraglutide injection (gSaxenda®) received by Biocon on February 24, 2026, enhancing the company’s portfolio of complex drug products.
Disclaimer: This article is based on a regulatory filing submitted to the National Stock Exchange of India (NSE).